CytoGenix expands DNA manufacturing
US biopharmaceutical company CytoGenix has announced breaking ground on a new $3.8m facility to expand the company's manufacturing capability of synthetic DNA.
Archives for September 4, 2007
Isis knocks diabetes receptor senseless
Isis Pharmaceuticals has initiated a Phase I safety study for its first-in-class antisense drug that aims to control blood glucose levels in patients with Type II diabetes.
Eden's bio garden grows
Britain's Eden Biodesign has been selected by Cancer Research UK as the beneficiary of two new biomanufacturing contracts as its biomanufacturing business continues to grow.
AstraZeneca increases affinity for China
AstraZeneca's affinity for China continues to escalate as the firm announced its first clinical pharmacology investment in the country.
Tata bags major BPO deal with Roche
Indian IT firm Tata Consultancy Services (TCS) has bagged its second high profile pharma outsourcing deal this year with a new multi-year contract with Swiss drug maker Roche.
ADHD transdermal patches withdrawn
Shire and Noven Pharmaceuticals have announced the voluntary withdrawal of a limited amount of Attention Deficit Hyperactivity Disorder (ADHD) transdermal patches following reports of a mechanical problem when applying the patch.
Novo Nordisk, Rheosciences, ImClone, Omrix Biopharmaceuticals, Biogen Idec and Human Genome Sciences, - People on the move
Novo Nordisk, Rheosciences, ImClone, Omrix Biopharmaceuticals, Biogen Idec and Human Genome Sciences, have all had people on the move in the biotech world.
Medarex, Centocor extend antibody deal
US biotech Medarex has announced it has extended its licensing deal with Centocor, giving the firm continued access to its antibody production technology.
Stada acquires Forum Bioscience Group
German pharmaceutical company Stada Arzneimittel has acquired British pharmaceutical Group Forum Bioscience Holdings for €55.6m.